BRM.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 21:05):

Stats
आज की मात्रा	6 585.00
औसत मात्रा	2 534.00
बाजार मूल्य	88.44B
EPS	€0 ( 2024-04-25 )
अगली कमाई की तारीख	( €0 ) 2024-07-26
Last Dividend	€0.570 ( 2023-07-06 )
Next Dividend	€0 ( N/A )
P/E	12.10
ATR14	€0.0880 (0.21%)

मात्रा सहसंबंध

लंबा: -0.06 (neutral)

छोटा: -0.46 (neutral)

Signal:(65.485) Neutral

Bristol-Myers Squibb Co सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Bristol-Myers Squibb Co सहसंबंध - मुद्रा/वस्त्र

0.50
( weak )

0.70
( moderate )

0.57
( weak )

0.71
( moderate )

-0.74
( moderate negative )

-0.78
( moderate negative )

Bristol-Myers Squibb Co वित्तीय

Annual	2023
राजस्व:	€45.01B
सकल लाभ:	€34.31B (76.24 %)
EPS:	€3.88

FY	2023
राजस्व:	€45.01B
सकल लाभ:	€34.31B (76.24 %)
EPS:	€3.88

FY	2022
राजस्व:	€46.16B
सकल लाभ:	€36.02B (78.04 %)
EPS:	€2.97

FY	2021
राजस्व:	€46.39B
सकल लाभ:	€36.45B (78.57 %)
EPS:	€3.15

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0.540 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0.570 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.68 - Stable (13.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.215	1999-06-30
Last Dividend	€0.570	2023-07-06
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	97	--
Total Paid Out	€33.94	--
Avg. Dividend % Per Year	0.00%	--
Score	4.93	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.68
Div. Directional Score	8.19	--

Next Divdend (Est)
(2024-05-08)

€0.580 Estimate 21.49 %

Dividend Stability

0.57 Average

Dividend Score

4.93

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PER.DE	Ex Dividend Knight	2023-07-05	Annually	0.00%
BAYN.DE	Ex Dividend Junior	2023-05-02	Annually	0.00%
HNR1.DE	Ex Dividend Junior	2023-05-04	Annually	0.00%
SCT.DE	Ex Dividend Knight	2023-07-27	Annually	0.00%
COK.DE	Ex Dividend Junior	2023-06-15	Annually	0.00%
KRN.DE	Ex Dividend Knight	2023-05-24	Annually	0.00%
185.DE	Ex Dividend Junior	2023-08-07	Quarterly	0.00%
TRVC.DE	Ex Dividend Junior	2023-08-04	Quarterly	0.00%
DYH.DE	Ex Dividend Knight	2023-11-14	Quarterly	0.00%
MUX.DE	Ex Dividend Junior	2023-07-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.43	9.65	[0 - 0.5]
returnOnAssetsTTM	0.0843	1.200	7.19	8.63	[0 - 0.3]
returnOnEquityTTM	0.263	1.500	8.19	10.00	[0.1 - 1]
payoutRatioTTM	0.591	-1.000	4.09	-4.09	[0 - 1]
currentRatioTTM	1.427	0.800	7.86	6.29	[1 - 3]
quickRatioTTM	1.237	0.800	7.43	5.94	[0.8 - 2.5]
cashRatioTTM	0.515	1.500	8.25	10.00	[0.2 - 2]
debtRatioTTM	0.436	-1.500	2.74	-4.11	[0 - 0.6]
interestCoverageTTM	8.08	1.000	8.12	8.12	[3 - 30]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.23	2.00	6.89	10.00	[0 - 20]
debtEquityRatioTTM	1.409	-1.500	4.36	-6.55	[0 - 2.5]
grossProfitMarginTTM	0.762	1.000	0.627	0.627	[0.2 - 0.8]
operatingProfitMarginTTM	0.209	1.000	7.82	7.82	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.334	1.000	9.25	9.25	[0.2 - 2]
assetTurnoverTTM	0.473	0.800	-0.180	-0.144	[0.5 - 2]
Total Score				10.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.47	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.263	2.50	8.84	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.23	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.258	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.82	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	0.591	1.500	4.09	-4.09	[0 - 1]
pegRatioTTM	0.194	1.500	-2.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.308	1.000	4.80	0	[0.1 - 0.5]
Total Score				5.68

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.